Century BC Room, Millennium Student Center, University of Missouri-St. Louis
1 University Blvd, St. Louis, MO 63121
The Joseph. B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.
St. Louis, MO
The Midwest CEPAC will convene in January 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
The California Technology Assessment Forum will convene to discuss ICER's report on treatments for Multiple Sclerosis. More information, including key dates for the report, will be available in the coming weeks.
ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a March 23, 2017 meeting of the New England CEPAC.
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on obeticholic acid (Intercept Pharmaceuticals, Inc.) for use in PBC and NASH.
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.
At its inaugural meeting, the Midwest CEPAC will convene to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.
The New England CEPAC convened on March 31, 2016 to discuss the comparative clinical effectiveness and value of outpatient palliative care.
The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5). The US Food and Drug Administration (FDA) approved mepolizumab in November 2015.
CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting on Thursday, October 29, 2015 to discuss the comparative effectiveness and value of two interventions for patients with congestive heart failure (CHF) – the drug Entresto (a combination of valsartan and sacubitril, Novartis AG), and the CardioMEMS HF System (St. Jude Medical). The CardioMEMS HF System is a heart failure monitor manufactured by St. Jude Medical and approved by the FDA in May, 2014. Entresto is a drug for the treatment of heart failure with reduced ejection fraction and was approved by the FDA on July 7, 2015.
Cardiovascular disease (CVD) is the most common cause of death in the United States and approximately one third of American adults have CVD. Low density lipoprotein cholesterol (LDL) is a major modifiable risk factor for myocardial infarction, stroke, and death from cardiovascular disease. The use of statins to decrease LDL has contributed to the marked decline in death from CVD since 1950, but some patients are not able to tolerate statins and others have inadequate reductions in LDL. In June 2015, the FDA advisory panel voted to recommend approval of two human monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) in the blood and markedly reduce LDL cholesterol levels.
The California Technology Assessment Forum (CTAF) held a public meeting on Tuesday, July 14, 2015 to discuss the comparative effectiveness and value of several current approaches to manage obesity, including medications, devices, and surgical procedures. ICER produced a report that includes a systematic review of the published evidence, as well as an economic analysis that examines cost-effectiveness and budget impact of the various approaches. The report formed the basis for deliberation and discussion at the public meeting, where the CTAF panel voted on key questions raised in the report, and a policy roundtable discussed evidence-based practice and policy recommendations.
Integration of behavioral health into primary care is designed to improve screening and treatment in primary care settings through systematic coordination and collaboration among health care providers to address both physical health and behavioral health needs. ICER’s report for New England CEPAC assesses the evidence on the comparative clinical effectiveness and value of efforts to integrate behavioral health into primary care; identifies the components potentially associated with successful integration; and evaluates the legal, regulatory, and financial landscape for behavioral health integration (BHI) throughout New England. The report also includes an overview of lessons learned from national and New England-based experts to identify potential innovations and solutions for BHI in the region.